DE3868037D1 - Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe. - Google Patents

Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.

Info

Publication number
DE3868037D1
DE3868037D1 DE8888403161T DE3868037T DE3868037D1 DE 3868037 D1 DE3868037 D1 DE 3868037D1 DE 8888403161 T DE8888403161 T DE 8888403161T DE 3868037 T DE3868037 T DE 3868037T DE 3868037 D1 DE3868037 D1 DE 3868037D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
active substance
delayed delivery
delayed
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888403161T
Other languages
English (en)
Inventor
Howard Stevens
Maryvonne Chariot
Francoise Arnold
Gareth Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Application granted granted Critical
Publication of DE3868037D1 publication Critical patent/DE3868037D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
DE8888403161T 1987-12-21 1988-12-13 Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe. Expired - Lifetime DE3868037D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8717855A FR2624732B1 (fr) 1987-12-21 1987-12-21 Formulation pharmaceutique a liberation prolongee

Publications (1)

Publication Number Publication Date
DE3868037D1 true DE3868037D1 (de) 1992-03-05

Family

ID=9358116

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888403161T Expired - Lifetime DE3868037D1 (de) 1987-12-21 1988-12-13 Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.

Country Status (23)

Country Link
US (1) US5112621A (de)
EP (1) EP0322277B1 (de)
JP (1) JPH082782B2 (de)
KR (1) KR960009650B1 (de)
AR (1) AR243378A1 (de)
AT (1) ATE71837T1 (de)
AU (1) AU609916B2 (de)
CA (1) CA1332567C (de)
DE (1) DE3868037D1 (de)
DK (1) DK172370B1 (de)
ES (1) ES2051881T3 (de)
FI (1) FI97445C (de)
FR (1) FR2624732B1 (de)
GR (1) GR3003826T3 (de)
HU (1) HU199685B (de)
IE (1) IE60313B1 (de)
IL (1) IL88736A (de)
IT (1) IT8723196A0 (de)
MX (1) MX169322B (de)
NO (1) NO179357C (de)
NZ (1) NZ227412A (de)
PT (1) PT89276B (de)
ZA (1) ZA889495B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145418A (ja) * 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
EP0452862B1 (de) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB2258613B (en) * 1991-08-12 1996-01-10 Euro Celtique Sa Pharmaceutical diltiazem formulation
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
JP3839467B2 (ja) * 1992-06-04 2006-11-01 スミスクライン・ビーチャム・コーポレイション 味の良い医薬組成物
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3264722B2 (ja) * 1993-02-25 2002-03-11 第一製薬株式会社 カプセル製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
FR2742660B1 (fr) 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
CZ300548B6 (cs) * 1998-03-26 2009-06-10 Astellas Pharma Inc. Prostredek s prodlouženým uvolnením makrolidové slouceniny
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
KR100407519B1 (ko) * 2001-08-31 2003-12-18 부광약품 주식회사 건조황산제일철과 방출조절제로서 엘-글루타민을 함유하는서방성 정제 및 그의 제조방법
KR100446818B1 (ko) * 2001-11-06 2004-09-01 김재윤 질산 이소소르비드 서방성 펠렛 제형
BRPI0415953B8 (pt) * 2003-10-29 2021-05-25 Wyeth Corp formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
KR100775957B1 (ko) * 2006-02-07 2007-11-13 경상대학교산학협력단 애기장대 유래의 개화시기를 조절 단백질 ｃｏ의 돌연변이단백질, 상기 단백질을 이용한 식물의 개화시기 조절전사인자의 분리방법 및 식물의 개화시기 조절방법
CN100442981C (zh) * 2006-11-09 2008-12-17 广东省昆虫研究所 一种德国小蠊毒饵
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
CN105452213B (zh) 2013-03-14 2017-09-22 阿尔克梅斯制药爱尔兰有限公司 富马酸酯前体药物及其在治疗多种疾病中的应用
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR101639163B1 (ko) * 2015-07-08 2016-07-22 울산대학교 산학협력단 저전송 영상 정보 및 센싱 정보 송수신 장치 및 이의 동작 방법
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
JPS625915A (ja) * 1985-07-03 1987-01-12 Nippon Iyakuhin Kogyo Kk 塩酸ジルチアゼム徐放性製剤及びその製法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Also Published As

Publication number Publication date
DK708088D0 (da) 1988-12-20
CA1332567C (en) 1994-10-18
FI97445C (fi) 1996-12-27
FR2624732B1 (fr) 1991-02-15
AU2707788A (en) 1989-06-22
ZA889495B (en) 1989-09-27
IL88736A (en) 1992-11-15
DK708088A (da) 1989-06-29
NO179357C (no) 1996-09-25
NZ227412A (en) 1989-12-21
AR243378A1 (es) 1993-08-31
GR3003826T3 (de) 1993-03-16
KR960009650B1 (en) 1996-07-23
ATE71837T1 (de) 1992-02-15
ES2051881T3 (es) 1994-07-01
FI97445B (fi) 1996-09-13
PT89276A (pt) 1989-12-29
IT8723196A0 (it) 1987-12-23
FI885884A (fi) 1989-06-22
IL88736A0 (en) 1989-07-31
US5112621A (en) 1992-05-12
IE60313B1 (en) 1994-06-29
JPH082782B2 (ja) 1996-01-17
HU199685B (en) 1990-03-28
FI885884A0 (fi) 1988-12-20
KR890009380A (ko) 1989-08-01
PT89276B (pt) 1993-12-31
FR2624732A1 (fr) 1989-06-23
EP0322277B1 (de) 1992-01-22
IE883810L (en) 1989-06-21
HUT49290A (en) 1989-09-28
EP0322277A1 (de) 1989-06-28
DK172370B1 (da) 1998-04-27
NO885641D0 (no) 1988-12-20
NO885641L (no) 1989-06-22
MX169322B (es) 1993-06-29
NO179357B (no) 1996-06-17
JPH02202A (ja) 1990-01-05
AU609916B2 (en) 1991-05-09

Similar Documents

Publication Publication Date Title
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
DE3676235D1 (de) Arzneizubereitung mit verzoegerter wirkstoffabgabe.
DE3688532D1 (de) Pharmazeutische darreichungsform mit verzoegerter abgabe.
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
DE122004000023I2 (de) Pharmazeutische Zusammensetzung
DE68901417D1 (de) Pharmazeutische zusammensetzung.
PT88404A (pt) Dosage form comprising fast agent delivery followed by slow agent delivery
DE3863963D1 (de) Pharmazeutische zusammensetzungen.
KR890701076A (ko) 온도-조절된 활성약제 디스펜서
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
DE3778723D1 (de) Leicht absorbierbare pharmazeutische zubereitung.
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
DE68909409T2 (de) Heilmitteldosierung zur verabreichung an fische.
DE3875108T2 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
DE68918847T2 (de) Stabile pharmazeutische zusammensetzung.
ATA80390A (de) Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
DE68902300D1 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
DE68915203D1 (de) Pharmazeutische Mischungen.
ATA133288A (de) Pharmazeutische zusammensetzung
DE58905160D1 (de) Pharmazeutische zubereitung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR